ESPE Abstracts

Introduction: 11-Beta-hydroxylase deficiency (CYP11B1) is the second most common cause of Congenital Adrenal Hyperplasia (CAH). Although the relative frequency of 11-OHD is reported as 3-5% of the cases of CAH, these numbers may have been somewhat underestimated.(1,2) The resultant clinical picture in 11-OHD is similar to that of 21-OHD, except for the variable presence of hypertension and hypokalemia due to DOC excess.(2,3)Aim o...

Background: Hypertension is a recognized complication in children with Congenital Adrenal Hyperplasia (CAH) due to 21-hydroxylase deficiency, treated with glucocorticoids and mineralocorticoids. This study aims to compare the clinical and laboratory characteristics of children with CAH who developed hypertension with those who maintained normal blood pressure (BP) over a treatment course.Methods: This retrospective cohor...

Background: Congenital Adrenal Hyperplasia (CAH) is a complex endocrine condition with varying presentations, one of which includes precocious puberty. Understanding how precocious puberty affects clinical parameters in pediatric CAH patients is crucial for optimizing management strategies.Methods: This study conducted a comprehensive statistical analysis comparing pediatric CAH patients with precocious puberty (n</e...